Breakthrough Psoriasis Data For Oral TYK2 Drug Might Change The Case For Investing In InnoCare Pharma (SEHK:9969)

Simply Wall St.07-29

In July 2026, InnoCare Pharma reported that its oral TYK2 allosteric inhibitor fadeucravacitinib (ICP-488) met the primary endpoint with statistically significant, clinically meaningful benefits and a...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2655286778?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-29 19:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655286778","market":"nz","top_or_hot":-1,"title":"Breakthrough Psoriasis Data For Oral TYK2 Drug Might Change The Case For Investing In InnoCare Pharma (SEHK:9969)","media":"Simply Wall St.","content":"<div>\n<p>In July 2026, InnoCare Pharma reported that its oral TYK2 allosteric inhibitor fadeucravacitinib (ICP-488) met the primary endpoint with statistically significant, clinically meaningful benefits and a...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/breakthrough-psoriasis-data-for-oral-tyk2-drug-might-change\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Breakthrough Psoriasis Data For Oral TYK2 Drug Might Change The Case For Investing In InnoCare Pharma (SEHK:9969)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBreakthrough Psoriasis Data For Oral TYK2 Drug Might Change The Case For Investing In InnoCare Pharma (SEHK:9969)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-29 19:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/breakthrough-psoriasis-data-for-oral-tyk2-drug-might-change><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In July 2026, InnoCare Pharma reported that its oral TYK2 allosteric inhibitor fadeucravacitinib (ICP-488) met the primary endpoint with statistically significant, clinically meaningful benefits and a...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/breakthrough-psoriasis-data-for-oral-tyk2-drug-might-change\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGIX","symbol_name":"通用人工智能 ETF-AGIX","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/breakthrough-psoriasis-data-for-oral-tyk2-drug-might-change","article_id":"2655286778","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/breakthrough-psoriasis-data-for-oral-tyk2-drug-might-change","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2655286778","pubTimestamp":1785323717,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In July 2026, InnoCare Pharma reported that its oral TYK2 allosteric inhibitor fadeucravacitinib (ICP-488) met the primary endpoint with statistically significant, clinically meaningful benefits and a consistent safety profile in a registrational Phase III trial for adults with moderate-to-severe plaque psoriasis.\nThis success further underscores InnoCare’s push into oral TYK2 therapies across multiple autoimmune skin diseases, potentially broadening its late-stage dermatology portfolio...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"AGIX":"通用人工智能 ETF-AGIX","QTOC":"Innovator Growth Accelerated Plus ETF - October","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","AIPO":"Defiance AI and Power Infrastructure ETF","BK1161":"生物科技","ARTY":"ISHARES FUTURE AI & TECH ETF","09969":"诺诚健华","BK1574":"生物医药B类股","VTHR":"Vanguard Russell 3000 ETF"},"translate_title":"口服 TYK2 药物突破性银屑病数据可能改变投资诺诚健华医药 (SEHK:9969)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARTY":0.73,"VTHR":0.73,"AIPO":0.83,"QTOC":0.73,"CHAT":0.73,"09969":0.9,"AGIX":0.73},"content_text":"In July 2026, InnoCare Pharma reported that its oral TYK2 allosteric inhibitor fadeucravacitinib (ICP-488) met the primary endpoint with statistically significant, clinically meaningful benefits and a consistent safety profile in a registrational Phase III trial for adults with moderate-to-severe plaque psoriasis. This success further underscores InnoCare’s push into oral TYK2 therapies across multiple autoimmune skin diseases, potentially broadening its late-stage dermatology portfolio beyond oncology-led revenue streams. We’ll now examine how this Phase III success for fadeucravacitinib in psoriasis could influence InnoCare Pharma’s broader investment narrative and growth priorities. This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.AdvertisementInnoCare Pharma Investment Narrative RecapTo own InnoCare, you need to believe its transition from an oncology-centric story toward a broader autoimmune and dermatology franchise can support the current valuation despite forecast earnings declines. The Phase III win for fadeucravacitinib in psoriasis strengthens the TYK2 narrative and may become a key nearer term catalyst, potentially easing concerns that high R&D spend and pipeline breadth might not translate into commercially relevant late stage assets. The recent Phase III success of soficitinib in moderate to severe atopic dermatitis is particularly relevant here, as it reinforces the TYK2 class across multiple skin diseases. Together with ICP 488 in psoriasis, this adds depth to InnoCare’s dermatology pipeline beyond orelabrutinib, which could help mitigate concentration risk if these programs move through regulatory review and into commercialization as planned. Yet, while these TYK2 wins are encouraging, investors should still be aware that... Read the full narrative on InnoCare Pharma (it's free!)InnoCare Pharma's narrative projects CN¥3.8 billion revenue and CN¥205.8 million earnings by 2029.Uncover how InnoCare Pharma's forecasts yield a HK$19.62 fair value, a 40% upside to its current price.Exploring Other PerspectivesSEHK:9969 1-Year Stock Price Chart While the psoriasis data could strengthen the TYK2 story, the most pessimistic analysts still saw earnings falling to about CN¥412.4 million by 2029 and margins compressing sharply, so you should expect very different interpretations of today’s news and be open to comparing several viewpoints before deciding what it means for you.Explore another fair value estimate on InnoCare Pharma - why the stock might be worth as much as 40% more than the current price!Decide For YourselfDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your InnoCare Pharma research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.Our free InnoCare Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate InnoCare Pharma's overall financial health at a glance.Ready For A Different Approach?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655286778","isCrawlerRequest":true}